HSD3B1 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 | Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
HSD3B2 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
ICAM1 | Intercellular adhesion molecule 1 | Cancer-related genes Candidate cardiovascular disease genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IL2RG | Interleukin 2 receptor, gamma | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ITGA2B | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ITGAL | Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ITGAV | Integrin, alpha V | Cancer-related genes CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ITGB3 | Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNC1 | Potassium voltage-gated channel, Shaw-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNJ1 | Potassium inwardly-rectifying channel, subfamily J, member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KIT | V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Mixed |
MAOA | Monoamine oxidase A | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Mixed |
MAOB | Monoamine oxidase B | Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Mixed |
MGAM | Maltase-glucoamylase (alpha-glucosidase) | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
MME | Membrane metallo-endopeptidase | Cancer-related genes Candidate cardiovascular disease genes CD markers Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
MS4A2 | Membrane-spanning 4-domains, subfamily A, member 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
NPC1L1 | NPC1-like 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Group enriched |
OPRM1 | Opioid receptor, mu 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
P2RY12 | Purinergic receptor P2Y, G-protein coupled, 12 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PDGFRB | Platelet-derived growth factor receptor, beta polypeptide | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
PROS1 | Protein S (alpha) | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
PSMD1 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
RYR1 | Ryanodine receptor 1 (skeletal) | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SCN2A | Sodium channel, voltage-gated, type II, alpha subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
SI | Sucrase-isomaltase (alpha-glucosidase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
SIGMAR1 | Sigma non-opioid intracellular receptor 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
SLC12A1 | Solute carrier family 12 (sodium/potassium/chloride transporter), member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC12A3 | Solute carrier family 12 (sodium/chloride transporter), member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC12A5 | Solute carrier family 12 (potassium/chloride transporter), member 5 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC22A8 | Solute carrier family 22 (organic anion transporter), member 8 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC5A2 | Solute carrier family 5 (sodium/glucose cotransporter), member 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC6A1 | Solute carrier family 6 (neurotransmitter transporter), member 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
SOAT1 | Sterol O-acyltransferase 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
SV2A | Synaptic vesicle glycoprotein 2A | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
SYT2 | Synaptotagmin II | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
TBXAS1 | Thromboxane A synthase 1 (platelet) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
TLR7 | Toll-like receptor 7 | FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
TNFRSF8 | Tumor necrosis factor receptor superfamily, member 8 | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
TNFSF11 | Tumor necrosis factor (ligand) superfamily, member 11 | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
TPO | Thyroid peroxidase | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
TYR | Tyrosinase | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |